PE20081378A1 - Derivados de 1,2,4-triazol como moduladores de mglur5 - Google Patents
Derivados de 1,2,4-triazol como moduladores de mglur5Info
- Publication number
- PE20081378A1 PE20081378A1 PE2007001288A PE2007001288A PE20081378A1 PE 20081378 A1 PE20081378 A1 PE 20081378A1 PE 2007001288 A PE2007001288 A PE 2007001288A PE 2007001288 A PE2007001288 A PE 2007001288A PE 20081378 A1 PE20081378 A1 PE 20081378A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- methyl
- triazole
- modulators
- etoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE [1,2,4]TRIAZOL DE FORMULA (I), EN DONDE R1 ES METILO, HALOGENO Y CIANO; R2 ES H Y FLUORO; R3 ES H Y ALQUILO(C1-C3); R4 ES H Y ALQUILO(C1-C3); R5 ES ALQUILO(C1-C3) Y CICLOPROPILO; X ES UN GRUPO a), b) O c); Z ES e), f), ENTRE OTROS; R6 ES H, ALQUILO(C1-C3), (C1-C3)HALOALQUILO, ENTRE OTROS; R7 ES H, ALQUILO(C1-C3), ENTRE OTROS. SON SELECCIONADOS: 4-(5-{(1R)-1-[5-(3-CLOROFENIL)ISOXAZOL-3-IL]ETOXI}-4-METIL-4H-1,2,4-TRIAZOL-3-IL)-1-METILPIRIDIN-2(1H)-ONA, 4-(5-{(1R)-1-[5-(3-CLOROFENIL)-1,2,4-OXADIAZOL-3-IL]ETOXI}-4-METIL-4H-1,2,4-TRIAZOL-3-IL)-1-METILPIRIMIDIN-2(1H)-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. ESTOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluRs), Y PRESENTAN UNA ACCION PREDOMINANTEMENTE PERIFERICA, SIENDO UTILES EN EL TRATAMIENTO DE REFLUJO ESOFAGICO, DOLOR, ANSIEDAD, SINDROME DE COLON IRRITABLE (IBS)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82832506P | 2006-10-05 | 2006-10-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20081378A1 true PE20081378A1 (es) | 2008-11-12 |
Family
ID=39032082
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007001288A PE20081378A1 (es) | 2006-10-05 | 2007-09-25 | Derivados de 1,2,4-triazol como moduladores de mglur5 |
Country Status (21)
Country | Link |
---|---|
US (1) | US7772235B2 (es) |
EP (1) | EP2079730A1 (es) |
JP (1) | JP2010505809A (es) |
KR (1) | KR20090060328A (es) |
CN (1) | CN101547916A (es) |
AR (1) | AR062965A1 (es) |
AU (1) | AU2007303889B2 (es) |
BR (1) | BRPI0719155A2 (es) |
CA (1) | CA2665083A1 (es) |
CL (1) | CL2007002757A1 (es) |
CO (1) | CO6220935A2 (es) |
IL (1) | IL197722A0 (es) |
MX (1) | MX2009003227A (es) |
NO (1) | NO20091626L (es) |
NZ (1) | NZ575657A (es) |
PE (1) | PE20081378A1 (es) |
RU (1) | RU2439068C2 (es) |
SA (1) | SA07280518B1 (es) |
TW (1) | TW200821305A (es) |
UY (1) | UY30610A1 (es) |
WO (1) | WO2008041075A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009054786A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole aryl n-oxides derivatives as modulators of mglur5 |
WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
WO2009054793A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Thiophene 1,2,4-triazole derivatives as modulators of mglur5 |
WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
WO2009054787A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole carboxylic acid derivatives as modulators of mglur5 |
KR20100089091A (ko) * | 2007-10-26 | 2010-08-11 | 아스트라제네카 아베 | Mglur5의 조절제로서의 아미노 1,2,4-트리아졸 유도체 |
KR20110040910A (ko) * | 2008-08-12 | 2011-04-20 | 아스트라제네카 아베 | 4-(5-((1r)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4h-1,2,4-트리아졸-3-일)피리딘의 결정질 형태 |
KR20110044864A (ko) * | 2008-08-12 | 2011-05-02 | 아스트라제네카 아베 | 4-(5-((1r)-1-[5-(3-클로로페닐)이속사졸-3-일]에톡시)-4-메틸-4h-1,2,4-트리아졸-3-일)피리딘의 신규 결정질 형태 |
CA2747507A1 (en) * | 2008-12-18 | 2010-06-24 | Astrazeneca Ab | New process for the preparation of 1- [5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanone and (r)-1-[5-(3-chloro-phenyl)-isooxazol-3-yl]-ethanol |
US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
IN2012DN03322A (es) * | 2009-09-21 | 2015-10-23 | Univ Vanderbilt | |
WO2012058128A2 (en) * | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Caprolactam mglur5 receptor modulators |
JP2013544891A (ja) | 2010-12-08 | 2013-12-19 | ヴァンダービルト ユニバーシティー | mGLUR5受容体のアロステリック調節剤としての二環式ピラゾール化合物 |
AU2011343477A1 (en) * | 2010-12-17 | 2013-07-04 | Vanderbilt University | Bicyclic triazole and pyrazole lactams as allosteric modulators of mGluR5 receptors |
US8471027B2 (en) | 2011-04-06 | 2013-06-25 | Hoffmann-La Roche Inc. | Adamantyl compounds |
EP2857387A1 (en) | 2013-10-07 | 2015-04-08 | Boehringer Ingelheim International Gmbh | Process for manufacturing 1,6-dihydro-6-oxo-4-pyridazine carboxylic acid |
WO2018010163A1 (zh) * | 2016-07-15 | 2018-01-18 | 泸州东方农化有限公司 | 一种1,2,4-***-3-硫酮化合物的合成方法及其中间体 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA87653C2 (en) * | 2002-08-09 | 2009-08-10 | Астразенека Аб | 1,2,4-oxadiazols as modulators of receptor-5 for metabotropic glutamate |
US7585881B2 (en) * | 2004-02-18 | 2009-09-08 | Astrazeneca Ab | Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
GB0514296D0 (en) | 2005-07-12 | 2005-08-17 | Novartis Ag | Organic compounds |
AR058807A1 (es) * | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
TW200808800A (en) | 2006-05-05 | 2008-02-16 | Astrazeneca Ab | MGluR5 modulators V |
-
2007
- 2007-09-21 TW TW096135382A patent/TW200821305A/zh unknown
- 2007-09-24 SA SA07280518A patent/SA07280518B1/ar unknown
- 2007-09-25 JP JP2009530956A patent/JP2010505809A/ja active Pending
- 2007-09-25 CL CL200702757A patent/CL2007002757A1/es unknown
- 2007-09-25 WO PCT/IB2007/002784 patent/WO2008041075A1/en active Application Filing
- 2007-09-25 PE PE2007001288A patent/PE20081378A1/es not_active Application Discontinuation
- 2007-09-25 AR ARP070104214A patent/AR062965A1/es not_active Application Discontinuation
- 2007-09-25 RU RU2009111113/04A patent/RU2439068C2/ru not_active IP Right Cessation
- 2007-09-25 NZ NZ575657A patent/NZ575657A/en not_active IP Right Cessation
- 2007-09-25 UY UY30610A patent/UY30610A1/es not_active Application Discontinuation
- 2007-09-25 EP EP07804973A patent/EP2079730A1/en not_active Withdrawn
- 2007-09-25 CN CNA2007800451517A patent/CN101547916A/zh active Pending
- 2007-09-25 MX MX2009003227A patent/MX2009003227A/es not_active Application Discontinuation
- 2007-09-25 KR KR1020097006875A patent/KR20090060328A/ko not_active Application Discontinuation
- 2007-09-25 AU AU2007303889A patent/AU2007303889B2/en not_active Ceased
- 2007-09-25 US US11/902,784 patent/US7772235B2/en not_active Expired - Fee Related
- 2007-09-25 BR BRPI0719155-3A patent/BRPI0719155A2/pt not_active IP Right Cessation
- 2007-09-25 CA CA002665083A patent/CA2665083A1/en not_active Abandoned
-
2009
- 2009-03-19 IL IL197722A patent/IL197722A0/en unknown
- 2009-04-23 NO NO20091626A patent/NO20091626L/no not_active Application Discontinuation
- 2009-04-29 CO CO09043380A patent/CO6220935A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY30610A1 (es) | 2008-05-02 |
MX2009003227A (es) | 2009-04-06 |
CL2007002757A1 (es) | 2008-06-20 |
JP2010505809A (ja) | 2010-02-25 |
NO20091626L (no) | 2009-05-04 |
SA07280518B1 (ar) | 2011-01-15 |
CA2665083A1 (en) | 2008-04-10 |
BRPI0719155A2 (pt) | 2014-02-04 |
CO6220935A2 (es) | 2010-11-19 |
AU2007303889A1 (en) | 2008-04-10 |
TW200821305A (en) | 2008-05-16 |
RU2009111113A (ru) | 2010-11-10 |
AU2007303889A2 (en) | 2010-07-15 |
EP2079730A1 (en) | 2009-07-22 |
IL197722A0 (en) | 2009-12-24 |
US7772235B2 (en) | 2010-08-10 |
US20080125436A1 (en) | 2008-05-29 |
KR20090060328A (ko) | 2009-06-11 |
RU2439068C2 (ru) | 2012-01-10 |
CN101547916A (zh) | 2009-09-30 |
AR062965A1 (es) | 2008-12-17 |
WO2008041075A1 (en) | 2008-04-10 |
AU2007303889B2 (en) | 2011-02-24 |
NZ575657A (en) | 2011-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20081378A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
RU2386622C2 (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
PE20081316A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
PE20060122A1 (es) | Compuestos de benzazepina como antagonistas del receptor de acetilcolina muscarinico m3 | |
PE20090884A1 (es) | Compuestos de indol como activadores de glucoquinasa | |
PE20080951A1 (es) | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS | |
PE20060770A1 (es) | Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1 | |
PE20090709A1 (es) | Compuestos heterociclico de 5 miembros | |
PE20021041A1 (es) | DERIVADOS DE DIHIDRO-BENZO[b][1,4]DIAZEPIN-2-0NA COMO ANTAGONISTAS II mGLUR2 | |
PE20060653A1 (es) | Derivados triciclicos condensados como moduladores del receptor 5-ht1 | |
PE20050525A1 (es) | Derivados de pirazol sustituido y compuestos relacionados como antagonistas del receptor de bradiquinina b1 | |
PE20080952A1 (es) | Amidas azociclicas fungicidas | |
PE20091429A1 (es) | 4-(4-ciano-2-tioaril)dihidropirimidinonas como inhibidores de la elastasa neutrofila humana (hne) | |
JP2006500348A5 (es) | ||
PE20091339A1 (es) | Derivados de oxadiazol con actividad sobre receptores s1p1 | |
PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
PE20081472A1 (es) | Compuestos de pirazolina | |
CO6140060A2 (es) | Derivados de aminocicloalquil 1,2,4-triazol como moduladores de mglur5 | |
PE20080360A1 (es) | Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |